The effects of the renin–angiotensin–aldosterone system blockers on serum ischemia-modified albumin levels in autosomal dominant polycystic kidney disease

Background Among one of the common hereditary causes of chronic kidney disease is autosomal-dominant polycystic kidney disease (ADPKD), and its incidence rate is reported as one between 500 and 1.000 individuals. The most common complications of ADPKD are hypertension (HT) and end-stage renal disease (ESRD). HT occurring in the early stage of ADPKD leads to deteriorations in renal function. Aims It was aimed to investigate the ischemia-modified albumin (IMA) levels and the effect of renin–angiotensin–aldosterone system (RAAS) blockers on serum IMA levels in patients with ADPKD. Methods One hundred and fifteen patients were included as ADPKD ( n = 50), HT ( n = 35), and healthy control (HC) groups ( n = 30). Patients with ADPKD and HT were divided into two subgroups as RAAS blocker-users and non-users. Results Serum IMA levels were detected as 0.42 (0.17–0.80) in ADPKD and 0.28 (0.04–0.51) in HT and 0.36 (0.22–0.56) in HC groups as absorbance units (ABSU), and the highest serum IMA level was seen in Group ADPKD. Serum IMA levels were 0.33 ± 0.14 in RAAS blocker-users and 0.41 ± 0.11 ABSU in non-users with ADPKD. Serum IMA levels were witnessed to be significantly lower in RAAS blocker-users in Groups ADPKD ( p = 0.038) and HT ( p = 0.004), compared to non-users. Given basal and 6-month values of those with ADPKD, the levels of serum IMA within 6 months were significantly lower ( p = 0.002). Conclusions We consider that serum IM levels should be assessed in oxidative stress (OS)-related conditions, such as ADPKD, and RAAS blockers may be effective in reducing serum IMA levels in ADPKD and HT patients.